Dr. Robert C. Long, M.D., PHARMD
Heart Failure & Transplant Cardiology (Advanced Heart Failure and Transplant Cardiology Physician)
- Medicare participating
At a glance
- Medical school
- University of Mississippi School of Medicine (2005)
- Years since graduation
- 21
- In the NPI registry since
- 2007
- Medicare patients seen, 2024
- 932
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2005Medical school: University of Mississippi School of Medicine
- 2007Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Advanced Heart Failure and Transplant Cardiology Physician primary
MS license 19752 -
Cardiovascular Disease Physician
MS license 19752 -
Internal Medicine Physician
MS license 19752 -
Pharmacist
MS license E09167
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Map: Heart Failure & Transplant Cardiology per capita by county →
Where they work
Hospitals
- Mississippi Baptist Medical Center Jackson, MS
- University of Mississippi Med Center Jackson, MS
- Southwest Ms Regional Medical Center Mccomb, MS
- Merit Health Madison Canton, MS
- Greenwood Leflore Hospital Greenwood, MS
Medical groups
- State of Mississippi - University of Mississippi Medical Center (965 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 932
- Services billed
- 2,549
- Patients’ average age
- 69
| Service | Times | Patients |
|---|---|---|
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 438 | 430 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | 188 | 58 |
| Ultrasound of heart with color-depicted blood flow, rate and valve function | 183 | 158 |
| Established patient office or other outpatient visit, 40-54 minutes | 178 | 134 |
| Ultrasound of heart blood flow, valves and chambers, follow-up | 170 | 145 |
| Ultrasound of heart, follow-up | 170 | 145 |
| Critical care, first 30-74 minutes | 95 | 23 |
| Heart muscle strain imaging | 44 | 42 |
| Insertion of tube in right heart chambers for measurement | 43 | 38 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | 31 | 31 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Spironolactone Other prescribers in Jackson, MS | 727 |
| Entresto (sacubitril/valsartan) Other prescribers in Jackson, MS | 671 |
| Farxiga (dapagliflozin propanediol) Other prescribers in Jackson, MS | 528 |
| Carvedilol Other prescribers in Jackson, MS | 469 |
| Furosemide Other prescribers in Jackson, MS | 362 |
| Losartan Potassium Other prescribers in Jackson, MS | 263 |
| Amlodipine Besylate Other prescribers in Jackson, MS | 258 |
| Atorvastatin Calcium Other prescribers in Jackson, MS | 223 |
| Pravastatin Sodium Other prescribers in Jackson, MS | 213 |
| Hydralazine Hcl Other prescribers in Jackson, MS | 208 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 25 companies reported 155 payments worth $94,738 in total to this clinician.
| Compensation for services other than consulting (speaking, faculty) | $70,670 |
|---|---|
| Consulting Fee | $12,361 |
| Travel and Lodging | $7,612 |
| Food and Beverage | $4,096 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Alnylam Pharmaceuticals Inc. Jun 2, 2025 | Compensation for services other than consulting (speaking, faculty) AMVUTTRA · Genetic Disease | $12,000 |
| AstraZeneca Pharmaceuticals LP Mar 11, 2025 | Consulting FeeCompany’s descriptionResearch Related Service | $6,981 |
| Alnylam Pharmaceuticals Inc. Dec 2, 2025 | Compensation for services other than consulting (speaking, faculty) | $6,000 |
| Merck Sharp & Dohme LLC Jul 23, 2025 | Compensation for services other than consulting (speaking, faculty) WINREVAIR · CARDIOVASCULAR | $5,760 |
| Merck Sharp & Dohme LLC Jul 23, 2025 | Compensation for services other than consulting (speaking, faculty) WINREVAIR · CARDIOVASCULAR | $5,760 |
| AstraZeneca Pharmaceuticals LP Mar 5, 2025 | Compensation for services other than consulting (speaking, faculty) FARXIGA · Cardiovascular and Metabolism Company’s descriptionSpeaker Fee | $4,300 |
| AstraZeneca Pharmaceuticals LP Mar 6, 2025 | Consulting FeeCompany’s descriptionResearch Related Service | $4,028 |
| Bayer HealthCare Pharmaceuticals Inc. Sep 27, 2025 | Compensation for services other than consulting (speaking, faculty) Adempas · Cardio-pulmonary | $3,920 |
| Alnylam Pharmaceuticals Inc. Sep 2, 2025 | Compensation for services other than consulting (speaking, faculty) AMVUTTRA · Genetic Disease | $3,750 |
| Alnylam Pharmaceuticals Inc. Nov 3, 2025 | Compensation for services other than consulting (speaking, faculty) AMVUTTRA · Genetic Disease | $3,750 |
All 51 payments other than meals, newest first
| Company | What it was for | Amount |
|---|---|---|
| Alnylam Pharmaceuticals Inc. Dec 2, 2025 | Compensation for services other than consulting (speaking, faculty) | $6,000 |
| Alnylam Pharmaceuticals Inc. Dec 2, 2025 | Travel and Lodging travel to Oxon Hill, MD | $724 |
| Alnylam Pharmaceuticals Inc. Dec 2, 2025 | Travel and Lodging travel to Oxon Hill, MD | $133 |
| Actelion Pharmaceuticals US, Inc. Nov 6, 2025 | Compensation for services other than consulting (speaking, faculty) UPTRAVI; OPSUMIT · Cardiology | $3,330 |
| Alnylam Pharmaceuticals Inc. Nov 3, 2025 | Compensation for services other than consulting (speaking, faculty) AMVUTTRA · Genetic Disease | $3,750 |
| Alnylam Pharmaceuticals Inc. Nov 3, 2025 | Travel and Lodging AMVUTTRA · Genetic Disease · travel to Meridian, MS | $150 |
| Alnylam Pharmaceuticals Inc. Oct 29, 2025 | Travel and Lodging travel to Oxon Hill, MD · in-kind | $962 |
| AstraZeneca Pharmaceuticals LP Oct 2, 2025 | Compensation for services other than consulting (speaking, faculty) LOKELMA · Cardiovascular and Metabolism Company’s descriptionSpeaker Fee | $2,150 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Oct 2, 2025 | Compensation for services other than consulting (speaking, faculty) JARDIANCE · DIABETES | $1,040 |
| Bayer HealthCare Pharmaceuticals Inc. Sep 30, 2025 | Consulting Fee Adempas · Cardio-pulmonary | $200 |
| Bayer HealthCare Pharmaceuticals Inc. Sep 27, 2025 | Compensation for services other than consulting (speaking, faculty) Adempas · Cardio-pulmonary | $3,920 |
| Bayer HealthCare Pharmaceuticals Inc. Sep 25, 2025 | Travel and Lodging Adempas · Cardio-pulmonary · travel to Columbus, MS · in-kind | $203 |
| Bayer HealthCare Pharmaceuticals Inc. Sep 20, 2025 | Travel and Lodging Adempas · Cardio-pulmonary · travel to Columbus, MS · in-kind | $197 |
| Alnylam Pharmaceuticals Inc. Sep 17, 2025 | Compensation for services other than consulting (speaking, faculty) AMVUTTRA · Genetic Disease | $3,750 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Sep 17, 2025 | Compensation for services other than consulting (speaking, faculty) JARDIANCE · DIABETES | $1,040 |
| Alnylam Pharmaceuticals Inc. Sep 2, 2025 | Compensation for services other than consulting (speaking, faculty) AMVUTTRA · Genetic Disease | $3,750 |
| Alnylam Pharmaceuticals Inc. Sep 2, 2025 | Travel and Lodging AMVUTTRA · Genetic Disease · travel to Hattiesburh, MS | $141 |
| Lilly USA, LLC Aug 27, 2025 | Compensation for services other than consulting (speaking, faculty) JARDIANCE · Diabetes | $1,040 |
| Merck Sharp & Dohme LLC Jul 23, 2025 | Compensation for services other than consulting (speaking, faculty) WINREVAIR · CARDIOVASCULAR | $5,760 |
| Merck Sharp & Dohme LLC Jul 23, 2025 | Compensation for services other than consulting (speaking, faculty) WINREVAIR · CARDIOVASCULAR | $5,760 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Jul 1, 2025 | Compensation for services other than consulting (speaking, faculty) JARDIANCE · DIABETES | $1,040 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Jun 10, 2025 | Compensation for services other than consulting (speaking, faculty) JARDIANCE · DIABETES | $1,040 |
| Alnylam Pharmaceuticals Inc. Jun 2, 2025 | Compensation for services other than consulting (speaking, faculty) AMVUTTRA · Genetic Disease | $12,000 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Jun 2, 2025 | Compensation for services other than consulting (speaking, faculty) JARDIANCE · DIABETES | $1,040 |
| Alnylam Pharmaceuticals Inc. Jun 2, 2025 | Travel and Lodging AMVUTTRA · Genetic Disease · travel to Boston, MA | $96.32 |
| Alnylam Pharmaceuticals Inc. Apr 26, 2025 | Travel and Lodging AMVUTTRA · Genetic Disease · travel to Boston, MA · in-kind | $29.14 |
| Alnylam Pharmaceuticals Inc. Apr 25, 2025 | Travel and Lodging AMVUTTRA · Genetic Disease · travel to Boston, MA · in-kind | $717 |
| Alnylam Pharmaceuticals Inc. Apr 25, 2025 | Travel and Lodging AMVUTTRA · Genetic Disease · travel to Boston, MA · in-kind | $243 |
| AstraZeneca Pharmaceuticals LP Apr 24, 2025 | Compensation for services other than consulting (speaking, faculty) LOKELMA · Cardiovascular and Metabolism Company’s descriptionSpeaker Fee | $2,150 |
| Merck Sharp & Dohme LLC Apr 21, 2025 | Consulting Fee | $1,152 |
| Lilly USA, LLC Apr 7, 2025 | Compensation for services other than consulting (speaking, faculty) JARDIANCE · Diabetes | $1,040 |
| Lilly USA, LLC Apr 7, 2025 | Compensation for services other than consulting (speaking, faculty) JARDIANCE · Diabetes | $1,040 |
| Lilly USA, LLC Mar 24, 2025 | Compensation for services other than consulting (speaking, faculty) JARDIANCE · Diabetes | $1,040 |
| Merck Sharp & Dohme LLC Mar 13, 2025 | Travel and Lodging WINREVAIR · CARDIOVASCULAR · travel to Philadelphia, PA | $150 |
| AstraZeneca Pharmaceuticals LP Mar 11, 2025 | Consulting FeeCompany’s descriptionResearch Related Service | $6,981 |
| Merck Sharp & Dohme LLC Mar 7, 2025 | Travel and Lodging WINREVAIR · CARDIOVASCULAR · travel to Philadelphia, PA · in-kind | $839 |
| Merck Sharp & Dohme LLC Mar 7, 2025 | Travel and Lodging WINREVAIR · CARDIOVASCULAR · travel to Philadelphia, PA · in-kind | $229 |
| Merck Sharp & Dohme LLC Mar 7, 2025 | Travel and Lodging WINREVAIR · CARDIOVASCULAR · travel to Philadelphia, PA · in-kind | $169 |
| Merck Sharp & Dohme LLC Mar 7, 2025 | Travel and Lodging WINREVAIR · CARDIOVASCULAR · travel to Philadelphia, PA · in-kind | $78.84 |
| AstraZeneca Pharmaceuticals LP Mar 6, 2025 | Consulting FeeCompany’s descriptionResearch Related Service | $4,028 |
| AstraZeneca Pharmaceuticals LP Mar 5, 2025 | Compensation for services other than consulting (speaking, faculty) FARXIGA · Cardiovascular and Metabolism Company’s descriptionSpeaker Fee | $4,300 |
| AstraZeneca Pharmaceuticals LP Mar 5, 2025 | Compensation for services other than consulting (speaking, faculty) FARXIGA · Cardiovascular and Metabolism Company’s descriptionSpeaker Fee | $1,050 |
| AstraZeneca Pharmaceuticals LP Feb 26, 2025 | Travel and Lodging FARXIGA · Cardiovascular and Metabolism · travel to Wilmington, DE · in-kind Company’s descriptionSpeaker Expenses | $673 |
| AstraZeneca Pharmaceuticals LP Feb 26, 2025 | Travel and Lodging FARXIGA · Cardiovascular and Metabolism · travel to Wilmington, DE · in-kind Company’s descriptionSpeaker Expenses | $646 |
| AstraZeneca Pharmaceuticals LP Feb 26, 2025 | Travel and Lodging FARXIGA · Cardiovascular and Metabolism · travel to Wilmington, DE · in-kind Company’s descriptionSpeaker Expenses | $211 |
| Lilly USA, LLC Feb 24, 2025 | Compensation for services other than consulting (speaking, faculty) JARDIANCE · Diabetes | $1,560 |
| Merck Sharp & Dohme LLC Feb 20, 2025 | Travel and Lodging WINREVAIR · CARDIOVASCULAR · travel to Fort Wayne, IN | $150 |
| Merck Sharp & Dohme LLC Feb 6, 2025 | Travel and Lodging WINREVAIR · CARDIOVASCULAR · travel to Fort Wayne, IN · in-kind | $733 |
| Merck Sharp & Dohme LLC Feb 6, 2025 | Travel and Lodging WINREVAIR · CARDIOVASCULAR · travel to Fort Wayne, IN · in-kind | $137 |
| Lilly USA, LLC Feb 5, 2025 | Compensation for services other than consulting (speaking, faculty) JARDIANCE · Diabetes | $1,040 |
| Lilly USA, LLC Jan 21, 2025 | Compensation for services other than consulting (speaking, faculty) JARDIANCE · Diabetes | $1,040 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 3 industry-funded studies in 2025, from 2 companies. The companies reported $71,652 in research payments for these studies, mostly to the institutions running them.
- ALLEVIATE-HF
Medtronic, Inc. - A multicenter, randomized, double-blind, parallel-group, placebo-controlled study to evaluate the efficacy and safety of finerenone on morbidity and mortality in participants with heart failure (NYHA II-IV) and left v…
Bayer HealthCare Pharmaceuticals Inc. - BAY 948862, A multicenter, randomized, double-blind, parallel-group, placebo-controlled study to evaluate the efficacy and safety of finerenone on morbidity and mortality in participants with heart failure (NYHA II-IV…
Bayer HealthCare Pharmaceuticals Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.